By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa - 2After toilet and email issues, Artemis II astronauts fire engine to head for the moon
- 3Antimatter took to the road for the very first time. Here’s why it matters
- 4Why are malnutrition deaths soaring in America?
- 5Mount Everest Climbers 'Poisoned' by Guides Prompting Mass Helicopter Rescues in $20 Million Insurance Fraud Scheme, Police Say
- Artemis II astronauts are more than halfway to the moon as they seek to break Apollo 13's record
- Fossils from China show complex life evolved millions of years earlier than once thought
- Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage
- Shrewd Home Gadgets to Save Energy
- The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- Astronomers detect black hole blasting winds at incredible speeds
- Was This Driver Simply Having Some good times Or Behaving Like An Ass?
- Ukrainian foreign minister appeals for funds for drones
